What is oral semaglutide?
Until now, semaglutide for weight loss (Wegovy) was only available as a weekly injection. The oral version delivers the same molecule in a daily pill, using SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) technology to protect the peptide molecule as it passes through the stomach acid.
The oral formulation was studied in the OASIS programme, showing weight loss results comparable to the injectable version — approximately 15% body weight loss over 68 weeks.
Why it matters
Needle aversion is a significant barrier to GLP-1 medication uptake. Surveys suggest 20–30% of people who would otherwise consider weight loss medication are deterred by the injection requirement. An oral option removes this barrier entirely.
It also changes the competitive landscape. Currently, the main advantage of oral medications (Duromine, Contrave, Xenical) is that they don't require injections — but they produce far less weight loss. Oral semaglutide would offer GLP-1-level effectiveness in a pill.
When will it come to Australia?
There is no confirmed timeline for Australian TGA approval or launch. Based on typical regulatory timelines:
- TGA submission: Expected 2026–2027
- TGA review: 6–12 months after submission
- Australian launch: Possibly 2027–2028 at the earliest
This is speculative. We'll update this page when Novo Nordisk announces Australian plans.
What should you do now?
If you're waiting for the oral version, it could be 1–2+ years. Injectable Wegovy and Mounjaro are available now and highly effective. The injection is a tiny needle that most patients find painless after the first couple of uses.